Mineralys Therapeutics, Inc. $MLYS Shares Sold by Quadrature Capital Ltd

Quadrature Capital Ltd reduced its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 83.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,987 shares of the company’s stock after selling 61,021 shares during the period. Quadrature Capital Ltd’s holdings in Mineralys Therapeutics were worth $162,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP raised its position in Mineralys Therapeutics by 32.8% during the first quarter. Wellington Management Group LLP now owns 121,557 shares of the company’s stock worth $1,930,000 after acquiring an additional 30,028 shares during the last quarter. Voya Investment Management LLC purchased a new position in shares of Mineralys Therapeutics during the 1st quarter worth approximately $255,000. Geode Capital Management LLC raised its position in shares of Mineralys Therapeutics by 19.0% during the 2nd quarter. Geode Capital Management LLC now owns 954,560 shares of the company’s stock worth $12,917,000 after purchasing an additional 152,560 shares during the last quarter. Strs Ohio purchased a new stake in Mineralys Therapeutics in the 1st quarter valued at approximately $359,000. Finally, Goldman Sachs Group Inc. lifted its stake in Mineralys Therapeutics by 166.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company’s stock valued at $4,739,000 after buying an additional 186,480 shares in the last quarter. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Jefferies Financial Group raised their price target on Mineralys Therapeutics from $15.00 to $26.00 and gave the stock a “hold” rating in a research report on Wednesday, September 3rd. Bank of America lifted their price objective on Mineralys Therapeutics from $38.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Wells Fargo & Company boosted their target price on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Wall Street Zen raised shares of Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $46.67.

Mineralys Therapeutics Price Performance

NASDAQ MLYS opened at $38.91 on Friday. The company has a market cap of $3.08 billion, a P/E ratio of -13.19 and a beta of 0.40. Mineralys Therapeutics, Inc. has a 12 month low of $8.24 and a 12 month high of $47.65. The company has a 50-day moving average of $41.27 and a 200-day moving average of $26.58.

Mineralys Therapeutics (NASDAQ:MLYS) last released its earnings results on Monday, November 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.14. As a group, equities research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Insider Buying and Selling at Mineralys Therapeutics

In other news, Director Daphne Karydas sold 15,000 shares of the firm’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $45.99, for a total value of $689,850.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Alexander M. Gold sold 12,742 shares of the business’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $46.50, for a total value of $592,503.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 1,416,793 shares of company stock worth $62,019,643. 25.56% of the stock is currently owned by company insiders.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.